Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.14
NAVB's Cash to Debt is ranked lower than
94% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. NAVB: 0.14 )
Ranked among companies with meaningful Cash to Debt only.
NAVB' s 10-Year Cash to Debt Range
Min: 0.14  Med: 1.87 Max: No Debt
Current: 0.14
Equity to Asset -3.28
NAVB's Equity to Asset is ranked lower than
99% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NAVB: -3.28 )
Ranked among companies with meaningful Equity to Asset only.
NAVB' s 10-Year Equity to Asset Range
Min: -3.6  Med: 0.43 Max: 0.94
Current: -3.28
-3.6
0.94
F-Score: 4
Z-Score: -50.98
M-Score: -1.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -352.12
NAVB's Operating margin (%) is ranked lower than
69% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. NAVB: -352.12 )
Ranked among companies with meaningful Operating margin (%) only.
NAVB' s 10-Year Operating margin (%) Range
Min: -35429.11  Med: -59.00 Max: 13.25
Current: -352.12
-35429.11
13.25
Net-margin (%) -409.87
NAVB's Net-margin (%) is ranked lower than
72% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. NAVB: -409.87 )
Ranked among companies with meaningful Net-margin (%) only.
NAVB' s 10-Year Net-margin (%) Range
Min: -36907.59  Med: -80.81 Max: 938.63
Current: -409.87
-36907.59
938.63
ROA (%) -161.71
NAVB's ROA (%) is ranked lower than
91% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. NAVB: -161.71 )
Ranked among companies with meaningful ROA (%) only.
NAVB' s 10-Year ROA (%) Range
Min: -502.64  Med: -47.73 Max: 26.69
Current: -161.71
-502.64
26.69
ROC (Joel Greenblatt) (%) -1108.65
NAVB's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. NAVB: -1108.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAVB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8007.05  Med: -277.79 Max: 145.59
Current: -1108.65
-8007.05
145.59
Revenue Growth (3Y)(%) 58.70
NAVB's Revenue Growth (3Y)(%) is ranked higher than
93% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. NAVB: 58.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAVB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100  Med: 0.00 Max: 89.8
Current: 58.7
-100
89.8
EBITDA Growth (3Y)(%) -8.00
NAVB's EBITDA Growth (3Y)(%) is ranked lower than
56% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. NAVB: -8.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAVB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -20.60 Max: 141
Current: -8
0
141
EPS Growth (3Y)(%) 8.10
NAVB's EPS Growth (3Y)(%) is ranked higher than
66% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. NAVB: 8.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAVB' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -4.40 Max: 112.7
Current: 8.1
0
112.7
» NAVB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014
Q3 2014
Q4 2014
Q1 2015
» Details

Insider Trades

Latest Guru Trades with NAVB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 43.00
NAVB's P/S is ranked lower than
78% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. NAVB: 43.00 )
Ranked among companies with meaningful P/S only.
NAVB' s 10-Year P/S Range
Min: 1.9  Med: 13.42 Max: 479
Current: 43
1.9
479
Current Ratio 0.62
NAVB's Current Ratio is ranked lower than
92% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. NAVB: 0.62 )
Ranked among companies with meaningful Current Ratio only.
NAVB' s 10-Year Current Ratio Range
Min: 0.62  Med: 2.90 Max: 17.92
Current: 0.62
0.62
17.92
Quick Ratio 0.58
NAVB's Quick Ratio is ranked lower than
90% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. NAVB: 0.58 )
Ranked among companies with meaningful Quick Ratio only.
NAVB' s 10-Year Quick Ratio Range
Min: 0.48  Med: 2.41 Max: 17.8
Current: 0.58
0.48
17.8
Days Inventory 263.31
NAVB's Days Inventory is ranked lower than
83% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. NAVB: 263.31 )
Ranked among companies with meaningful Days Inventory only.
NAVB' s 10-Year Days Inventory Range
Min: 70.99  Med: 128.48 Max: 1386.56
Current: 263.31
70.99
1386.56
Days Sales Outstanding 57.92
NAVB's Days Sales Outstanding is ranked higher than
53% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. NAVB: 57.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAVB' s 10-Year Days Sales Outstanding Range
Min: 9.77  Med: 59.28 Max: 1211.54
Current: 57.92
9.77
1211.54

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.19
NAVB's Price/Median PS Value is ranked lower than
85% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NAVB: 3.19 )
Ranked among companies with meaningful Price/Median PS Value only.
NAVB' s 10-Year Price/Median PS Value Range
Min: 0.05  Med: 0.34 Max: 26.87
Current: 3.19
0.05
26.87
Earnings Yield (Greenblatt) (%) -10.05
NAVB's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NAVB: -10.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NAVB' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -14.1  Med: 0.00 Max: 0
Current: -10.05
-14.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Navidea Biopharmaceuticals Inc was incorporated in Ohio in 1983 and reincorporated in Delaware in 1988. It is a biopharmaceutical company engaged in the development and commercialization of precision diagnostics and radiopharmaceutical agent. Its products include Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help evaluate patients with breast cancer and melanoma. Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on macrophages. This flexible and versatile platform acts as an engine for the design of purpose-built molecules offering the potential to be utilized across a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography, intra-operative and/or optical-fluorescence detection in a variety of disease states. NAV4694 is a Fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. NAV5001 is an Iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinson's disease and other movement disorders, with potential use as a diagnostic aid in dementia. NAV1800 is a radiolabeled monoclonal antibody being developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, with a focus on colorectal cancer. It faces competition from medical product and biotechnology companies, as well as from universities and other non-profit research organizations in the field of cancer diagnostics and treatment. As a developer, manufacturer and marketer of medical products, the Company is subject to regulation by, among other governmental entities, FDA and the corresponding state, local and foreign regulatory bodies in jurisdictions in which its products are sold.
» More Articles for NAVB

Headlines

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 
comment on NAVB Mar 15 2013 

More From Other Websites
Navidea Awarded $1.7 Million Fast Track NIH SBIR Grant for Evaluation of Manocept™ in Rheumatoid... Jul 29 2015
7:31 am Navidea Biopharma awarded $1.7 mln fast track NIH SBIR grant for evaluation of Manocept in... Jul 29 2015
Navidea Awarded $1.7 Million Fast Track NIH SBIR Grant for Evaluation of Manocept™ in Rheumatoid... Jul 29 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Jul 28 2015
Navidea and Massachusetts General Hospital to Evaluate Manocept™ for Detection of Cardiovascular... Jul 28 2015
Navidea and Massachusetts General Hospital to Evaluate Manocept™ for Detection of Cardiovascular... Jul 28 2015
Verification of Lymphoseek® Mechanism of Action Published in Journal of Immunology Jul 23 2015
Verification of Lymphoseek® Mechanism of Action Published in Journal of Immunology Jul 23 2015
Navidea Biopharmaceuticals to Announce Second Quarter 2015 Financial Results on July 30, 2015 Jul 22 2015
Navidea Biopharmaceuticals to Announce Second Quarter 2015 Financial Results on July 30, 2015 Jul 22 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jul 21 2015
Navidea Biopharmaceuticals Announces 2015 Annual Meeting Results Jul 16 2015
Navidea Biopharmaceuticals Announces 2015 Annual Meeting Results Jul 16 2015
Partnerships Rather Than Buyouts May Become Big Pharma's Choice In Collaborating With Biotechs Jul 12 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jul 08 2015
Navidea Biopharmaceuticals and Macrophage Therapeutics to Host Post-International KSHV Conference... Jul 07 2015
Navidea Biopharmaceuticals and Macrophage Therapeutics to Host Post-International KSHV Conference... Jul 07 2015
Navidea Biopharmaceuticals and Macrophage Therapeutics to Host Post-International KSHV Conference... Jul 02 2015
Navidea Biopharmaceuticals and Macrophage Therapeutics to Host Post-International KSHV Conference... Jul 02 2015
Macrophage Therapeutics Reports Data Demonstrating a Manocept™ Drug Conjugate Induces Apoptosis in... Jul 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK